STAT+: FDA\u2019s \u2018key man\u2019 Peter Marks is out. Biotech investors will now deal with the consequences
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency\u2019s leadership ranks and threatens to unmoor the oversight of drugs and vaccines from bedrock scientific principles.\u00a0<\/p>\n
For biotech investors, Marks\u2019 ouster<\/a> is a worst-case scenario realized \u2014 an FDA riven by dysfunction and uncertainty. And it comes at a time when the sector is already suffering through a years-long public markets slump<\/a>.\u00a0<\/p>\n A crisis in confidence<\/a> at the FDA is potentially calamitous. Investing in biopharma companies becomes exceedingly difficult if the regulatory agency in charge of evaluating and approving life-saving (and money-making) medicines stops following predictable, well-established standards.<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n